BackWelgene Biotech ,Ltd. Overview

Welgene Biotech ,Ltd. Receivables

Latest receivables for 6661.TWO: $41M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$41.16M
↓ 14.12% YoYΔ $-6.77M vs prior year quarter

Peer trimmed avg / median

Loading

Welgene Biotech ,Ltd. Receivables History

Loading

Welgene Biotech ,Ltd. vs. peers: Receivables Comparison

Loading

Welgene Biotech ,Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Welgene Biotech ,Ltd. (6661.TWO) FAQ

Welgene Biotech ,Ltd. (6661.TWO) currently reports a receivables of $41M as of June 2026. That compares with $48M in the prior-year period — down 14.1% year over year. Use the charts on this page to explore Welgene Biotech ,Ltd.'s receivables history and peer comparisons.

Welgene Biotech ,Ltd.'s receivables decreased from $48M to $41M — a 14.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Welgene Biotech ,Ltd. reported $41M in receivables as of June 2026. That compares with $48M in the prior-year period — down 14.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $41M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Welgene Biotech ,Ltd., and consider following 6661.TWO for alerts when major investors trade the stock.